Ecosystem Over Geography: Life Sciences Location Strategy in APAC

• Demographics are reshaping demand unevenly. Japan has entered super-aged society status (c.30% of total population over 65), while Australia, China, Singapore, South Korea, Hong Kong, and Taiwan are aging rapidly. Simultaneously, non-communicable disease burden is rising across emerging markets, creating divergent therapeutic opportunities across the region.
• Innovation and capital are concentrating, not dispersing. Four countries—China, Japan, India, and Australia—account for 95% of domestic life sciences R&D spending. China attracted $8.6 billion in venture capital between 2023 and 2025, concentrated in Shanghai, Beijing, and the Greater Bay Area. India's contract research revenue surged to $7.5 billion.
• Regulatory environments create three distinct market tiers. Gateway markets (Singapore, Hong Kong) offer transparent pathways but limited scale. Selective-entry markets (China, India, Australia, South Korea, Philippines, Indonesia and Vietnam) provide large commercial opportunities but require significant compliance resources. Frontier markets (Japan, New Zealand) impose restrictive timelines or pricing controls that constrain returns.
• Location strategies are aligning across five critical dimensions: Five dimensions determine location readiness: demographic demand, regulatory environment, R&D innovation access, specialized talent availability, and capital access. India leads in talent but has regulatory complexity. China dominates venture capital funding but requires high compliance overhead. Singapore and Hong Kong offer regulatory clarity but limited sociodemographic opportunity. Location strategy requires deliberate trade-off decisions, not one-market solutions. 
• Implication for corporate real estate leaders: Location strategy must prioritize proximity to established talent ecosystems and specialized infrastructure over cost optimization or geographic diversification. The markets that will dominate Asia-Pacific life sciences have already emerged. Strategic positioning within these hubs is time-sensitive.

"Life sciences" encompasses three fundamentally different business models – although for many companies, all three are intertwined within the same organization:

Biotech and pharmaceutical organizations compete on speed – getting approved therapies to patients faster than anyone else. This demands sustained R&D investment, the ability to navigate complex regulatory systems, and access to clinical trial infrastructure. Medicine consumption across APAC is growing at 1.4% annually, but growth is heavily skewed toward China at 2.9% while Japan is essentially flat¹. For pharma companies, this distribution directly shapes where to make capacity investment.

Medtech and medical devices organizations compete on reliability and speed-to-market. High-risk devices (Class III) require GMP-certified cleanrooms with advanced HVAC and longer lead times than low-risk devices. The medtech market in APAC is forecast to hit roughly $128 billion by 2029², with growth spread across orthopaedics, diagnostic imaging, and consumables. But not all markets can support high-complexity device manufacturing.

Contract research and manufacturing organizations have become essential to the entire ecosystem. They take on the specialized work—clinical trials, regulatory navigation, manufacturing—that other companies prefer to outsource. China and India now account for 91% of all APAC contract research organization revenue, with China growing 40% between 2019 and 2025 (reaching $3.1 billion) and India surging to $7.5 billion³. 

The real estate infrastructure demands vary dramatically across these models —some spaces require significant capital investment and longer lead times, while others can operate from standard commercial facilities. Not every market in Asia has built out the facilities that life sciences companies need.

For decades, life sciences companies have expanded across the region relatively freely, establishing operations where labour was cheap or markets seemed promising. But looking forward, companies' location strategies are realigning around five specific factors.

Demographics
 

Asia-Pacific's aging populations are reshaping patient demographics across developed and upper-middle-income markets. Japan has crossed into super-aged territory with 29.99% of its population over 65. Hong Kong (23.67%), South Korea (20.33%), Australia (17.31%), China (14.91%) and Singapore (14.62%) are all experiencing rapid aging. This demographic shift creates substantial demand for therapies addressing age-related conditions—cardiovascular disease, cognitive decline, mobility disorders—and shapes where certain markets will see the strongest opportunity.

At the same time, disease burden is rising unevenly across the region. Non-communicable diseases—diabetes, respiratory disease, mental health conditions—are increasing at different rates depending on local factors. Thailand saw an 11% increase in disease burden between 2019 and 2023. India, Indonesia, and Vietnam are experiencing rising disease prevalence as economic development and urbanization accelerate lifestyle-related conditions. 

These demographic and epidemiological patterns shape which markets will demand which therapies. But location decisions are equally driven by innovation access, talent, and regulation Demographics inform which markets to serve, not where to place operations.

Regulatory environment
 

Regulatory systems in APAC fall into three tiers, and this dramatically affects the timeline and capital requirements. 

Gateway markets like Singapore and Hong Kong offer transparent regulatory pathways and market-driven pricing. Getting approved and to market is straightforward—and expensive, but predictable. These markets are ideal entry points for companies new to APAC or for establishing regional regulatory headquarters.

Selective-entry markets—China, India, Australia, South Korea, Philippines, Indonesia and Vietnam —offer much larger commercial opportunities but require navigating significant regulatory friction and pricing controls. You'll need dedicated compliance resources and local regulatory expertise. But the markets are big enough to justify the investment.

Frontier markets like Japan and New Zealand have either restrictive regulatory approval processes or government pricing controls that limit what you can earn. Japan is a case in point: transparent regulation but glacially slow approval timelines. This creates a real competitive disadvantage for innovative companies where speed matters.

Time-to-approval is the hidden competitive lever here. India has become a clinical trial hub precisely because its regulatory system enables rapid enrolment. Companies can run studies faster and cheaper than in most developed markets. China's regulatory reforms have accelerated approvals for innovative therapies. Japan's system, while predictable, is slow. These differences add up to months or years in life sciences companies’ new drug or therapy development timeline.

R&D capabilities
 

Over decades, specific cities in APAC have built specialized infrastructure—research hospitals, university partnerships, supplier ecosystems—that enables innovation velocity. Companies have chosen to locate near these clusters to gain advantage.

Number of active clinical trials

Source: BMI

China, Japan, India, and Australia—account for 95% of domestic life sciences R&D⁴ spending and 68% of active clinical trials. China has invested heavily in biotech innovation and now leads in clinical trial volume and growth. India's clinical trial capacity is expanding rapidly as companies recognize cost and population advantages. Japan maintains mature, well-established R&D ecosystem. Australia has strong capabilities in specific therapeutic areas. Within these countries, innovation activities cluster in specific cities, that is Shanghai, Beijing, and Suzhou in China; Tokyo, Osaka, and Kyoto in Japan; Mumbai, Hyderabad, and Bengaluru in India; Melbourne, Sydney, and Perth in Australia. Proximity to established innovation clusters fundamentally affects the speed and quality of research output—factors that directly determine market leadership and competitiveness in life sciences sector.

Specialized talents
 

The geographic concentration of life sciences talent creates significant location constraints. India and China together command the majority of APAC's life sciences workforce, reflecting distinct pathways to talent development.

China's dominance stems from two converging forces. Over the past two decades, the country has dramatically expanded its higher education infrastructure, creating a large pool of science and engineering graduates. Simultaneously, China's complex regulatory environment—marked by stringent drug approval processes and clinical trial requirements—has necessitated deep technical expertise across functions from regulatory affairs to clinical development. This combination has generated a sizeable talent base spanning R&D, manufacturing, quality assurance, and regulatory roles. 

India's talent advantage follows a different trajectory. India's pharmaceutical heritage created an established workforce in drug development and manufacturing, now expanded into biotech and clinical research. Additionally, India's strong English proficiency, cost-competitive talent, and growing IT integration skills have made it a magnet for back-office functions, clinical operations, and digital health initiatives. Yet like China, India's specialized talent clusters in specific cities: Bangalore for biotech innovation, Mumbai for pharmaceutical operations, and Hyderabad for contract research services.

Companies must locate near these talent concentrations—dispersing operations risks talent shortages and expertise access.

Venture capital funding
 

Venture capital funding for life sciences in APAC is highly concentrated. Between 2023 and 2025, China attracted $4.9 billion in venture capital funds for life sciences—far exceeding any other APAC market. Mega-funding rounds cluster in Greater Shanghai ($3.1 billion), Beijing ($512 million), and the Greater Bay Area ($405 million). India's Ahmedabad has emerged as a secondary hub with $270 million of venture capital funding raised. Australia, Japan, and other markets attract meaningful but significantly smaller venture capital funding flows.

Being in a major funding hub reduces friction, accelerates capital flow, and strengthens negotiating position. Being distant from capital increases travel burden, makes it harder to build investor relationships, and raises capital costs. For companies building venture-backed businesses in life sciences, location strategy must account for where growth capital flows and factor that into broader location decisions.

The convergence of demographics, regulatory complexity, innovation ecosystems, talent concentration, and capital flows has fundamentally altered the calculus for life sciences real estate and location strategy in Asia-Pacific. Success requires deliberate positioning within concentrated hubs where competitive advantages compound.

For corporate real estate leaders, this shift has three critical implications.

Facilities as competitive infrastructure

Life sciences real estate is not fungible. GMP-certified cleanrooms for high-risk medical devices, BSL-2/BSL-3 wet labs for biologics development, and climate-controlled pharmaceutical warehousing require specialized construction, regulatory compliance, and operational protocols. These facilities cannot be rapidly established in markets lacking existing infrastructure. Corporate real estate leaders must evaluate facility availability and lead times as primary constraints in market entry decisions. Markets without established life sciences real estate ecosystems present existential barriers that talent or capital cannot overcome.

Location strategy is now driven by talent ecosystem access

China and India dominate Asia-Pacific's specialized life sciences workforce, with talent concentrated in specific urban clusters: Shanghai, Beijing, and Suzhou in China; Bangalore, Mumbai, and Hyderabad in India. Attempting to establish R&D or specialized manufacturing operations outside these ecosystems—even with comparable facilities—results in persistent talent shortages and knowledge isolation. Real estate strategy must prioritize proximity to deep talent pools over cost arbitrage. Facility decisions should follow workforce availability, not precede it.

Market timing and first-mover advantage

Venture capital, regulatory capacity, and innovation infrastructure are concentrating in a narrow set of geographies. Companies establishing operations in Shanghai, Beijing, Bangalore, or Mumbai today secure access to evolving ecosystems where R&D partnerships, supplier networks, and regulatory expertise will continue to deepen. The opportunity to secure strategic real estate positions in these markets is time-bound as sector consolidation is happening faster than ever before.

For corporate real estate leaders, the path forward requires taking concentrated bets on ecosystem-rich locations. The markets that matter have already emerged. The question is whether companies will position themselves accordingly before access costs become prohibitive.

¹IQVIA: The Global Use of Medicines 2025: Outlook to 2029 (August 2025)

²BMI: Asia Medical Devices Report (April 2026)

³Source: Evaluate Pharma

⁴Source: Evaluate Pharma